ClinicalTrials.Veeva

Find clinical trials for Eczema in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias
Psoriasis

Eczema trials near Nashville, TN, USA:

Status recently updated
Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Enrolling
Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

Murfreesboro, Tennessee, United States and 35 other locations

Locations recently updated

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Tralokinumab
Drug: Placebo

Phase 3

LEO Pharma
LEO Pharma

Nashville, Tennessee, United States and 52 other locations

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....

Active, not recruiting
Atopic Dermatitis Eczema
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Phase 3

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Murfreesboro, Tennessee, United States and 91 other locations

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: ANB032
Drug: Placebo

Phase 2

AnaptysBio
AnaptysBio

Nashville, Tennessee, United States and 30 other locations

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Active, not recruiting
Atopic Dermatitis (AD)
Drug: Ruxolitinib Cream

Phase 3

Incyte
Incyte

Murfreesboro, Tennessee, United States and 37 other locations

Status recently updated

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Begins enrollment this month
Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Murfreesboro, Tennessee, United States and 105 other locations

Locations recently updated

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination...

Enrolling
Atopic Dermatitis
Drug: Omeprazole
Drug: Metoprolol

Early Phase 1

Amgen
Amgen

Nashville, Tennessee, United States and 6 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Phase 3

Pfizer
Pfizer

Murfreesboro, Tennessee, United States and 559 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Goodlettsville, Tennessee, United States and 318 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Hermitage, Tennessee, United States and 333 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems